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ABSTRACT 
Background  
Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic 
stroke, prior studies have found low rates of administration. Recent guidelines and regulatory 
agencies have advocated for increased tPA administration in appropriate patients, but it is 
unclear how many patients actually receive tPA. 
Objective 
To determine whether national rates of tPA use for ischemic stroke have increased over time. 
Methods 
We identified all patients with a primary diagnosis of ischemic stroke from years 2001-2006 in 
the National Hospital Discharge Survey, a nationally representative sample of inpatient 
hospitalizations, and searched for procedure codes for intravenous thrombolytic administration. 
Clinical and demographic factors were obtained from the survey and multivariable logistic 
regression used to identify independent predictors associated with thrombolytic use. 
Results 
Among the 22,842 patients hospitalized with ischemic stroke, tPA administration rates increased 
from 0.87% in 2001 to 2.40% in 2006 (p<0.001 for trend).  Older patients were less likely to 
receive tPA (adjusted odds ratio and 95% confidence interval (OR) = 0.4 [0.3-0.6] for patients ≥ 
80 years vs. < 60 years), as were African-American patients (OR=0.4 [0.3-0.7]). Larger hospitals 
were more likely to administer tPA (OR=3.3 [2.0-5.6] in hospitals with at least 300 beds 
compared to those with 6-99 beds).  
Conclusions   
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Although tPA administration for ischemic stroke has increased nationally in recent years, the 
overall rate of use remains very low. Larger hospitals were more likely to administer tPA. 
Further efforts to improve appropriate administration of tPA should be encouraged, particularly 
as the acceptable time-window for using tPA widens. 
 
Page 5 of 20
John Wiley & Sons, Inc.
Journal of Hospital Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60For Peer Review Only
  6 
Background 
Recombinant tissue plasminogen activator (tPA), approved for use in the United States 
for the treatment for acute ischemic stroke since 1996, improves overall outcomes from ischemic 
stroke when administered to selected patients
1-4.  Several prominent guidelines, including the 
Brain Attack Coalition and the American Stroke Association, have recommended increasing the 
use of tPA for acute ischemic stroke
5-7.  In addition, in 2003 the Joint Commission on 
Accreditation of Healthcare Organizations developed a disease-specific certification program to 
designate certain institutions “Primary Stroke Centers”, with one of the performance measures 
being the availability of thrombolysis
8.   
Despite guidelines and regulatory agencies promoting the use of thrombolysis for 
ischemic stroke, previous studies have shown disappointingly low rates of use
9-12.  The goals of 
this study were to assess whether national trends in the use of thrombolysis for acute ischemic 
stroke have increased in light of increased regulatory activity as well as to identify patient 
characteristics associated with thrombolytic administration. 
 
Materials and Methods 
Data for this study were obtained from the 2001 through 2006 National Hospital 
Discharge Survey (NHDS), a nationally representative sample of inpatient hospitalizations 
conducted annually by the National Center for Health Statistics
13.  The NHDS collects data from 
approximately 300,000 patients from about 500 short-stay nonfederal hospitals in the United 
States and uses a 3 stage sampling strategy that allows for extrapolation to national level 
estimates. Response rates typically exceed 90% from participating hospitals.  The survey collects 
demographic data, including age, sex, race, hospital geographic region, hospital bedsize and 
Page 6 of 20
John Wiley & Sons, Inc.
Journal of Hospital Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60For Peer Review Only
  7 
patient insurance status. In addition, up to 7 diagnostic and 4 procedural codes from the 
hospitalization are available, as is hospitalization length of stay and patient discharge disposition.  
No information on timing of symptoms, degree of neurologic compromise, or results of imaging 
tests were available in the NHDS. 
We searched for all patients aged 18 years or older with a primary diagnostic code of 
ischemic stroke using the International Classification of Diseases, 9
th Edition, Clinical 
Modification (ICD-9-CM) codes 433, 434, 436, 437.0, and 437.1, excluding codes with a fifth 
digit of 0 (which indicated arterial occlusion without mention of cerebral infarction).  We then 
searched for the presence of an ICD-9-CM procedure code for injection or infusion of 
thrombolytic agent (code 99.10).  Specific comorbid conditions associated with ischemic stroke 
were identified by searching for specific ICD-9-CM codes, including for heart failure, coronary 
artery disease, hypertension, diabetes mellitus, and atrial fibrillation. To provide a general 
assessment of the severity of illness of the patients, we calculated an adapted Charlson 
comorbidity score for each patient using available secondary discharge diagnosis codes
14. We 
also searched for codes corresponding to intracranial hemorrhage, a complication associated with 
tPA administration.  
 
Statistical Analysis 
We defined thrombolytic utilization rates as the number of patients hospitalized with a 
primary diagnosis of ischemic stroke who had a procedure code for thrombolysis divided by the 
total number of patients hospitalized with ischemic stroke.  To calculate nationally representative 
prevalence rates, we used the sample weights provided by the NHDS to account for the complex 
sampling design of the survey.  Differences in thrombolytic administration rates by patient and 
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hospital characteristics were tested using chi-squared tests for categorical variables and t-tests for 
continuous variables.  Variables underwent a backwards selection process with a significance 
level of 0.05 to develop the final multivariable model of predictors of thrombolytic 
administration.  Length of stay and hospital discharge status were not included in the variable 
selection process, as the focus was on predictors of initial administration of thrombolytics. All 
analyses were conducted using SAS Version 9.1 (SAS Institute Inc., Cary, NC).   
 
Results 
From years 2001 through 2006, we identified 22,842 patients with a primary diagnosis of 
ischemic stroke.  Of these, 313 (1.37%, 95% confidence interval [CI]: 1.22%-1.53%) had a 
procedure code for injection or infusion of thrombolysis. Using NHDS sample weights, these 
numbers corresponded to an estimated 2.55 million hospitalizations for ischemic stroke in the 
United States during the time period and to 35,082 patients receiving intravenous thrombolytics. 
Although the overall rate of thrombolysis administration was quite low overall, the 
administration rate increased over time, from 0.87% [95%CI: 0.61%-1.22%] of stroke patients in 
year 2001 to 2.40% [95%CI: 1.95-2.93%] in year 2006 and with a particular increase especially 
noted after year 2003 (p<0.001 for trend, Figure 1).   
On bivariate analysis, a lower proportion of African-American patients received tPA 
compared to white patients (0.8% vs. 1.5%, p=0.003), while a higher proportion of patients with 
atrial fibrillation received tPA (2.3% vs. 1.2%, p<0.001).  Older patients were less likely than 
younger patients to receive tPA (Table 1). The rate of intracranial hemorrhage was significantly 
higher in patients who received tPA (5.4% vs. 0.6%, p<0.001) and the overall inpatient mortality 
in patients who received tPA was 9.0%. Mortality in patients receiving tPA continued to be 
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higher than in patients who did not receive tPA even when patients with intracranial hemorrhage 
were excluded (8.1% vs. 5.3%, p<0.001).  Larger hospitals were more likely to administer tPA to 
patients with ischemic stroke, with a 1.79% administration rate in hospitals with ≥ 300 beds 
compared to 0.90% in hospitals with 100-199 beds and 0.52% in hospitals with 6-99 beds 
(p<0.001). 
  After adjusting for patient and hospital characteristics, the absolute rate of thrombolysis 
administration increased by an average of 0.19% per year [95% confidence interval 0.12%-
0.26%]. Factors that were significantly associated with administration of thrombolytics included 
being hospitalized in a larger hospital, having a history of atrial fibrillation, and a higher 
Charlson comorbidity index (Table 2). Patients aged 80 years or older, African-American 
patients, and those with diabetes mellitus were significantly less likely to receive thrombolysis. 
 
Discussion 
Despite strong recommendations from guidelines and regulatory agencies, national rates 
of intravenous thrombolysis for ischemic stroke continue to be quite low overall.  However, tPA 
administration appears to have increased from previous years and particularly increased in years 
after the Joint Commission began to accredit institutions as “Primary Stroke Centers”
11. The 
oldest patients and African-Americans were less likely to receive thrombolytics, while patients 
with atrial fibrillation were more likely to receive thrombolysis, potentially related to atrial 
fibrillation causing more severe strokes
15. Five point four percent of patients who received tPA 
were diagnosed with intracranial hemorrhage, and the inpatient mortality rate of patients with 
tPA was 9.0%.  
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The exact optimal rate of thrombolysis administration for the patients in our study is 
unknown, as the NHDS database lacked detailed information on factors that would preclude tPA 
administration such as late timing of presentation and mild stroke symptoms
3. Studies conducted 
in stroke registries and regional settings have found that only approximately 15%-32% of 
patients presenting with ischemic stroke arrive within 3 hours of symptom onset, and of these, 
only about 40%-50% are eligible for tPA clinically
9, 10, 16-19.  However, even among presumed 
eligible patients, tPA administration rates only range between 25% and 43%
17, 19, 20, and the ideal 
rate is likely to be higher than the very low rates we observed in our study. Newer evidence that 
extending the time window where tPA may be given safely may increase the number of eligible 
patients
21.  
Patients who received thrombolysis had higher mortality rates than patients who did not. 
Although we were unable to determine a causal association, prior observational studies of tPA 
administration for acute stroke have found that patients with more severe neurologic deficits 
were more likely to receive thrombolysis
17,18. The 9.0% inpatient case-fatality rate observed in 
our study compares favorably to the 13.4% mortality rate after tPA reported in a post-approval 
meta-analysis of safety outcomes
22 and the rate of intracranial hemorrhage in our analysis was 
similar to those observed in other settings
9, 22-25.  We were unable to determine whether 
intracranial hemorrhages in our study were as a result of tPA administration or whether patients 
who received tPA were more likely to have intracranial hemorrhages detected, such as may be 
due to increased frequency of head imaging. 
Larger hospitals were more likely to administer tPA. This may reflect regionalization of 
stroke care, particularly in those designated as stroke “centers of excellence”. As well, there is 
some evidence that there is a “learning curve” with thrombolysis administration, where 
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guideline-recommended practice and use of tPA increases with additional experience with the 
drug
9, 26. Promoting systems that allow for rapid triage and diagnosis of acute stroke should be 
encouraged and hospital leaders should develop strategies that allow for early recognition of 
potential tPA candidates. 
There are several limitations to our analysis. The NHDS does not collect detailed data on 
clinical or presenting features of stroke, and so we lacked information on stroke severity and 
eligibility for administration of thrombolysis.  Our study may have underestimated the overall 
rates of thrombolysis, as it was dependent on diagnostic codes.  A previous study of 34 patients 
who received tPA found that although the 99.10 code was 100% specific, the code identified 
only 17 patients who actually received tPA (sensitivity of 50%)
20. Another study comparing 
Medicare administrative claims data to actual pharmacy billing charges for tPA found that 
administrative data underestimated the rate of tPA administration by about 25%-30%
12. If a 
diagnostic code sensitivity of 50% was assumed, rates of tPA administration in our study may 
have been as high as 4.8% [95% CI: 4.1%-5.5%] by year 2006. 
 In conclusion, the use of intravenous thrombolysis in patients admitted with acute 
ischemic stroke in the United States has risen over time, but overall use remains very low. 
Further efforts to improve appropriate administration rates should be encouraged, particularly as 
the acceptable time-window for using tPA widens. 
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Figure 1. Proportion of patients admitted with a primary diagnosis of ischemic stroke who 
received thrombolysis  
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Table 1.  Clinical characteristics of 22,842 patients with a primary diagnosis of ischemic stroke 
 
  Thrombolysis 
N (%) 
No thrombolysis 
N (%) 
P value 
Age      0.001 
< 60  76  (24.3)  4478  (19.9)   
60-69  73  (23.3)  3942  (17.5)   
70-79  82  (26.2)  6265  (27.8)   
80+  82  (26.2)  7844  (34.8)   
Female  155  (49.5)  12625 (56.0)  0.02 
Race      0.003 
White  173  (55.3)  11542  (51.2)   
African-American  29  (9.3)  3774  (16.8)   
Other  16  (5.1)  814  (3.6)   
Not stated   95  (30.4)  6399  (28.4)   
Region      0.05 
Northeast  78  (24.9)  4570  (20.3)   
Midwest  84  (26.8)  6924  (30.7)   
South  104  (33.2)  8284  (36.8)   
West  47  (15.0)  2751  (12.2)   
Type of admission      <0.001 
Emergent  247  (78.9)  14233  (63.2)   
Urgent  33  (10.5)  3703  (16.4)   
Elective  5  (1.6)  1346  (6.0)   
Unknown  28  (9.0)  3247  (14.4)   
Length of stay, days [95% CI]  7.2  [6.6-7.8]  6.0  [5.9-6.1]  <0.001 
Hospital bedsize      <0.001 
6-99  16  (5.1)  3065  (13.6)   
100-199  48  (15.3)  5289  (23.5)   
200-299  86  (27.5)  5212  (23.1)   
300+  163  (52.1)  8963  (39.8)   
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Payment type      <0.001 
Medicare  176  (56.2)  15197  (67.5)   
Medicaid  21  (6.7)  1245  (5.5)   
Private  45  (14.4)  2483  (11.0)   
HMO/PPO  39  (12.5)  2224  (9.9)   
Other/unknown  32  (10.2)  1380  (6.1)   
Discharge status      <0.001 
Home  98  (31.3)  9507  (42.2)   
Short term care facility  25  (8.0)  1271  (5.6)   
Long term care facility  62  (19.8)  5400  (24.0)   
Alive, status unknown  89  (28.4)  4514  (20.0)   
Death  28  (9.0)  1218  (5.4)   
Unknown  11  (3.5)  619  (2.8)   
Comorbid conditions       
Congestive heart failure  48  (15.3)  2769  (12.3)  0.10 
Coronary artery disease  49  (15.7)  4082  (18.1)  0.26 
Hypertension  164  (52.4)  12480  (55.4)  0.29 
Diabetes mellitus  42  (13.4)  4965  (22.0)  <0.001 
Atrial fibrillation  96  (30.7)  4096  (18.2)   <0.001 
Intracranial hemorrhage  17  (5.4)  139  (0.6)  <0.001 
Charlson score (mean)  2.48  [2.32-2.64]  2.38  [2.36-2.40]  0.23 
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Table 2. Independent predictors of receiving thrombolysis in 22,842 hospitalized patients with a 
primary diagnosis of ischemic stroke 
Characteristic  Adjusted odds ratio and 95% confidence 
intervals 
Year (per year, from 2001 to 2006)  1.2  [1.1-1.3] 
Age   
<60  Referent 
60-69  1.0  [0.7-1.4] 
70-79  0.6  [0.5-0.9] 
80+  0.4  [0.3-0.6] 
Race   
Not African-American  Referent 
African-American  0.4  [0.3-0.7] 
Unknown  1.0  [0.8-1.2] 
Hospital bedsize   
6-99  Referent 
100-199  1.7  [1.0-3.1] 
200-299  3.2  [1.8-5.4] 
300+  3.3  [2.0-5.6] 
Diabetes mellitus  0.5  [0.3-0.6] 
Atrial fibrillation  2.2  [1.7-2.9] 
Charlson comorbidity score
14 (per point increase)  1.1  [1.1-1.2] 
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